ADAR1 Capital Management, LLC, a 10%+ owner of Tenax Therapeutics, Inc. (TENX), disclosed another open-market purchase of the company’s stock in a Form 4 filing. On September 3, 2026, the investment firm bought 900,000 shares at $1.78 apiece, a transaction worth $1,604,160.00. Following the purchase, ADAR1 holds 6,524,151 shares indirectly, through a trust or affiliated … Read more
ADAR1 Capital Management, LLC, a 10%+ owner of Tenax Therapeutics, Inc. (TENX), disclosed another open-market purchase of the small-cap biopharmaceutical company’s stock in a Form 4 filed with the SEC. On August 24, 2026, the investment firm bought 107,374 shares at $1.75 apiece, an outlay of $188,355.47 paid from its own funds rather than acquired … Read more
NextCure, Inc. (NXTC) is showing up on our radar after ADAR1 Capital Management, LLC, a 10%+ owner of the company, made another open-market purchase of the biotech’s shares. On July 31, 2026, ADAR1 bought 3,300 shares at $4.98 apiece, a purchase worth $16,420.14. Following the trade, ADAR1’s indirectly held stake in NextCure stands at 689,416 … Read more